AI Article Synopsis
Article Abstract
Purpose: The purpose of this study was the development and physicochemical and immunological characterization of intranasal (i.n.) vaccine formulations of whole inactivated influenza virus (WIV) coated with N,N,N-trimethyl chitosan (TMC).
Methods: Synthesized TMCs with a degree of quarternization of 15% (TMC15) or 37% (TMC37) were tested in vitro for their ability to decrease the transepithelial resistance (TEER) of an epithelial cell monolayer. TMC15- and TMC37-coated WIV (TMC15-WIV and TMC37-WIV) were characterized by zeta potential measurements, dynamic light scattering, electron microscopy and gel permeation chromatography. Mice were vaccinated i.n. with selected vaccine formulations and immunogenicity was determined by measuring serum hemagglutination inhibition (HI) and serum IgG, IgG1 and IgG2a/c titers. Also a pulse-chase study with TMCs in solution administered i.n. 2 h prior to WIV was performed. Protective efficacy of vaccination was determined by an aerosol virus challenge.
Results: TMC37 induced a reversible decrease in TEER, suggesting the opening of tight junctions, whereas TMC15 did not affect TEER. Simple mixing of (negatively charged) WIV with TMC15 or TMC37 resulted in positively charged particles with TMCs being partially bound. Intranasal immunization with TMC37-WIV or TMC15-WIV induced stronger HI, IgG, IgG1 and IgG2a/c titers than WIV alone. TMC37-WIV induced the highest immune responses. Both TMC15-WIV and TMC37-WIV provided protection against challenge, whereas WIV alone was not protective. Intranasal administration of TMC prior to WIV did not result in significant immune responses, indicating that the immunostimulatory effect of TMC is primarily based on improved i.n. delivery of WIV.
Conclusions: Coating of WIV with TMC is a simple procedure to improve the delivery and immunogenicity of i.n. administered WIV and may enable effective i.n. vaccination against influenza.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11095-009-9845-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
Vaccine
December 2024
USDA-ARS, National Animal Disease Center, Virus and Prion Research Unit, Ames, IA, USA. Electronic address:
Influenza A viruses (IAV) of subtypes H1N1, H1N2, and H3N2 are endemic in US domestic swine populations and contribute to significant economic losses annually and pose a persistent pandemic threat. Adjuvanted, whole-inactivated virus (WIV) vaccines are the primary countermeasure to control IAV in swine. The compositions of these vaccines are matched for hemagglutinin (HA) strain and content, often ignoring the other IAV glycoprotein, the neuraminidase (NA).
View Article and Find Full Text PDFAssessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system.
Vaccine
January 2025
Department of Medical Microbiology & Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address:
Article Synopsis
- In vitro systems using human peripheral blood mononuclear cells (PBMCs) can effectively evaluate vaccine responses, particularly focusing on B cells alongside T cells and antigen-presenting cells.
- The study investigated how B cells in PBMCs respond to different influenza vaccine formulations (whole inactivated virus vs. split virus) and the impact of the adjuvant CpG ODN 2395 on immune responses.
- Findings revealed that WIV stimulated better B cell differentiation and higher antibody production compared to SIV, with the combination of WIV and CpG leading to the most significant immune responses, highlighting the potential of using PBMCs in early vaccine evaluations.
Modulating the >Co(II)/Co(III) redox cycling via confinement of cobalt with WS for the ultrafast sulfite activation.
Sci Total Environ
October 2023
College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
Sulfite autoxidation in combination with the cobalt-based heterogeneous activators, has recently emerged as the efficient sulfate radical (SO) generation process for organic micropollutant abatement in the water and wastewater treatment, yet the sluggish >Co(II)/Co(III) redox cycling currently compromises the efficacy of radical generation and the potential applications. Herein, regarding that the reductive W(IV) species in WS can modulate the >Co(II)/Co(III) redox cycling in the advanced oxidation processes, confinement of cobalt with WS (Co-WS) is designed and characterized. The Co-WS/sulfite process achieves an ultrafast tetracycline (TC) abatement (~100 % abatement of TC within 1 min) under circumneutral conditions with lower dosage of sulfite and activator, outperforming the current cobalt-based heterogeneous counterparts.
View Article and Find Full Text PDFAdjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs.
Vaccines (Basel)
September 2024
Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA.
Invariant natural killer T (iNKT) cells are glycolipid-reactive T cells with potent immunoregulatory properties. iNKT cells activated with the marine-sponge-derived glycolipid, α-galactosylceramide (αGC), provide a universal source of T-cell help that has shown considerable promise for a wide array of therapeutic applications. This includes harnessing iNKT-cell-mediated immune responses to adjuvant whole inactivated influenza virus (WIV) vaccines.
View Article and Find Full Text PDFAn effective vaccine against influenza A virus based on the matrix protein 2 (M2).
Vet Microbiol
November 2024
Department of Biochemistry, 505 South Goodwin Avenue, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA.
The ever-increasing antigenic diversity of the hemagglutinin (HA) of influenza A virus (IAV) poses a significant challenge for effective vaccine development. Notably, the matrix protein 2 (M2) is a highly conserved 97 amino acid long transmembrane tetrameric protein present in the envelope of IAV. More than 99 % of IAV strains circulating in American swine herds share the identical pandemic (pdm) isoform of M2, making it an ideal target antigen for a vaccine that could elicit broadly protective immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!